Autres langues NFL Biosciences

Actions

ALNFL

FR0014003XT0

Recherche biotechnologique et médicale

PEA

PEA/PME

Marché Fermé - Euronext Paris Autres places de cotation 17:55:00 30/06/2026			Varia. 5j.	Varia. 1 janv.
0,8700 ^EUR	-0,11 %		+0,58 %	-26,15 %

18:35	NFL Biosciences finalise la fabrication d'un lot clinique BPF de NFL-102 et valide sa chaîne de production industrielle	CI
17:57	NFL Biosciences valide la production industrielle du NFL-102 contre la tabagisme

Autres langues

18:35	NFL Biosciences Successfully Manufactures GMP Clinical Batch Of NFL-102 And Validates Industrial Production Chain
17:46	NFL Biosciences Announces the Successful Manufacturing of a GMP Clinical Batch of NFL-102 and Validates Its Industrial Production Chain
01/06	NFL Biosciences Releases New Results on NFL-101 and Reaffirms Its Personalized Approach to Smoking Cessation
01/06	NFL Biosciences Releases New Results on NFL-101 and Reaffirms Its Personalized Approach to Smoking Cessation
26/05	NFL Biosciences to File Patent Application for Smoking Cessation Drug-linked Biomarker
25/05	NFL Biosciences Is Strengthening Its Personalized Medicine Approach to Smoking Cessation With a New Patent Application
25/05	NFL Biosciences Files Patent Application Protecting Predictive Efficacy Biomarker Associated With NFL-101
11/05	NFL Biosciences SA Clarifies Objectives And Evaluation Criteria For Predictive Biomarker Associated With NFL-101
11/05	NFL Biosciences Clarifies the Objectives and Evaluation Criteria for a Predictive Biomarker Associated With NFL-101
04/05	NFL Biosciences: International Scientific Community’s Interest in NFL-102 for Smoking Cessation Confirmed by the Selection of Its Work at Two Leading Conferences
04/05	NFL Biosciences Presents Work On NFL-102 For Smoking Cessation At International Scientific Conferences
15/04	NFL Biosciences SA Reports Earnings Results for the Full Year Ended December 31, 2025
15/04	NFL Biosciences Presents Its 2025 Annual Results and Provides an Update on Its Clinical Progress Driven by a New Paradigm in Smoking Cessation
15/04	NFL Biosciences Strengthens Its Cash Position by €2.6 Million Through Bond Financing Subscribed by a Group of European Institutional Investors
15/04	NFL Biosciences SA announced that it expects to receive ?2.6 million in funding from Vester Finance
13/04	Weekly Earnings Calendar: JPMorgan and Netflix in the US, LVMH and ASML in Europe,
07/04	A New Paradigm in Tobacco and Nicotine Addiction: NFL Biosciences Demonstrates the Mechanism of Action of NFL-102 in a Video
11/03	NFL BIOSCIENCES Secures EUR 500,000 Loan from Bpifrance
11/03	NFL Biosciences : Inside Information / Other news releases
11/03	Bpifrance Renews Its Confidence in NFL Biosciences Through the Granting of a €500,000 Loan
19/02	NFL Biosciences Publishes Its 2026 Financial Agenda
26/01	NFL Biosciences SA Significantly Raises Its Efficacy Targets for Smoking Cessation
26/01	NFL Biosciences Significantly Raises Its Efficacy Targets for Smoking Cessation
08/12	NFL Biosciences Obtains Complementary Characterization Results for NFL-101, its first-in-class Drug Candidate for Smoking Cessation, and Prepares a New Patent Application
08/12	NFL Biosciences SA Obtains Complementary Characterization Results for NFL-101, its First-In-Class Drug Candidate for Smoking Cessation, and Prepares A New Patent Application